Abstract
Background: Guidelines discourage prediction of neurological outcome in comatose patients within the first 72 h after cardiac arrest. Increasing evidence suggests that patients with the most severe brain injury and those with no or minimal brain injury may be identified before 72 h using novel methods. We present a protocol for the EARLY-NEURO study, which aims to evaluate whether good and poor outcomes can be reliably predicted already from 24 h after cardiac arrest using the most commonly available methods. Methods: Protocol for a prospective international multicenter substudy within the Sedation, TEmperature and Pressure after Cardiac Arrest and REsuscitation (STEPCARE) trial where adults post-arrest are randomized to minimal or deep sedation, fever treatment with or without a temperature management device and to two different targets of mean arterial blood pressure. Patients sedated or still unconscious at 24 h are examined with head computed tomography (CT) and electroencephalogram (EEG). Blood samples are collected at 24 h after randomization, and stored for analysis of the brain injury marker neurofilament light. CT and EEG examinations will be centrally evaluated for signs of a likely poor or good outcome applying standardized criteria by raters blinded to treatment allocations and patient outcomes. Intensive care treatment, neurological prognostication, and criteria for withdrawal of care will be according to the STEPCARE protocol. Timepoint and reasons for withdrawal of life-sustaining therapy (WLST) will be recorded. WLST prior to 72 h after randomization based on a presumed futile neurological prognosis is strongly discouraged. Primary outcome will be good or poor functional outcome, assessed by the modified Rankin Scale (dichotomized as 0–3 versus 4–6) at 6 months. Results will be reported in accordance with the Standards for Reporting Diagnostic Accuracy (STARD). Conclusions: Earlier prognostication aims to balance the avoidance of premature treatment withdrawal in patients with favorable potential against the prevention of unnecessary intervention in patients with a definitely poor prognosis.
| Originalsprache | Englisch |
|---|---|
| Aufsatznummer | e70239 |
| Zeitschrift | Acta Anaesthesiologica Scandinavica |
| Jahrgang | 70 |
| Ausgabenummer | 5 |
| Seiten (von - bis) | e70239 |
| ISSN | 0001-5172 |
| DOIs | |
| Publikationsstatus | Veröffentlicht - 05.2026 |
Fördermittel
The STEPCARE trial is funded by The Swedish Research Council, The Swedish Heart-lung Foundation, ALF-project funding within the Swedish Health Care, The Academy of Finland, Sigrid Jusélius Foundation (Finland), Hospital District of Helsinki and Uusimaa (Finland), Medicinska Understödsföreningen Liv och Hälsa (Sweden), Medical Research Future Fund (Australia), Health Research Council of New Zealand, the Clinical Research Programme Directorate of Health Ministry of Health and Social Security (Luxembourg), the Regional Research Council of Region Halland, and the Fondation Cœur-Daniel Wagner under the aegis of the Fondation de Luxembourg (Luxembourg). The STEPCARE EARLY-NEURO study is further funded by regional research funds in the Scania region, and the Skane University Hospital Foundations. The STEPCARE trial is funded by The Swedish Research Council, The Swedish Heart‐lung Foundation, ALF‐project funding within the Swedish Health Care, The Academy of Finland, Sigrid Jusélius Foundation (Finland), Hospital District of Helsinki and Uusimaa (Finland), Medicinska Understödsföreningen Liv och Hälsa (Sweden), Medical Research Future Fund (Australia), Health Research Council of New Zealand, the Clinical Research Programme Directorate of Health Ministry of Health and Social Security (Luxembourg), the Regional Research Council of Region Halland, and the Fondation Cœur‐Daniel Wagner under the aegis of the Fondation de Luxembourg (Luxembourg). The STEPCARE EARLY‐NEURO study is further funded by regional research funds in the Scania region, and the Skane University Hospital Foundations. Markus Skrifvars received a speakers fee from BARD Medical (Ireland) 2022 and is a member of the editorial board of Acta Anaesthesiologica Scandinavica. Christoph Leithner has received research support from the Laerdal Foundation. Jens Nee reports receiving lecture fees from BD and Becton Dickinson GmbH. No further conflicts of interest were reported.
| Träger | Trägernummer |
|---|---|
| Fondation Cœur-Daniel Wagner | |
| Regional Research Council of Region Halland | |
| Skane University Hospital Foundations | |
| Laerdal Foundation | |
| Research Council of Finland | |
| Medicinska Understödsföreningen Liv och Hälsa | |
| Health Research Council of New Zealand | |
| Fondation de Luxembourg (Luxembourg) | |
| Health Ministry of Health and Social Security (Luxembourg) | |
| Medical Research Future Fund | |
| Hospital District of Helsinki and Uusimaa | |
| Hjärt-Lungfonden | |
| Vetenskapsrådet | |
| Sigrid Juséliuksen Säätiö |
UN SDGs
Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung
-
SDG 3 – Gesundheit und Wohlergehen
Strategische Forschungsbereiche und Zentren
- Zentren: Universitäres Herzzentrum Lübeck (UHZL)
DFG-Fachsystematik
- 2.22-12 Kardiologie, Angiologie
Fingerprint
Untersuchen Sie die Forschungsthemen von „Early Prediction of Neurological Outcome After Cardiac Arrest-Rationale and Design of the Prospective International Observational EARLY-NEURO, a STEPCARE Substudy“. Zusammen bilden sie einen einzigartigen Fingerprint.Zitieren
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver